Hopes For Glaxo’s MAGE-A3 Vaccine Grow Dim As Trial Misses Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo’s vaccine fails co-primary endpoint in Phase III DERMA study of melanoma – trial is allowed to continue but hopes for success are not high. Top-line release raises specter that drug could become yet another failed cancer vaccine.
You may also be interested in...
Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it puts more pressure on the company to deliver on its respiratory launches.
Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it put more pressure on the company to deliver on its respiratory launches.
Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.